March 29, 2024
Taiho Pharmaceutical’s Lonsurf (trifluridine + tipiracil) has earned a label update to reflect its clinical benefits demonstrated in a pivotal trial evaluating its combination therapy with bevacizumab for the treatment of unresectable, advanced or relapsed colorectal cancer. The “clinical studies”...read more